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Introduction {#sec001}
============

Head and neck cancer affects approximately 750,000 new patients worldwide every year with the most common type being head and neck squamous cell carcinoma (HNSCC), a frequently lethal cancer that develops in the epithelial linings of the oral cavity, pharynx, and larynx \[[@pone.0170091.ref001], [@pone.0170091.ref002]\]. Although HNSCC is by far strongly associated with tobacco use and heavy alcohol consumption, in the last two decades, the role of high-risk human papillomaviruses (HPV) is emerged as an important etiological factor for a subset of HNSCC arising from the oropharynx. The incidence of HPV-driven oropharyngeal SCC (OPSCC) is dramatically increasing in developed countries predominantly affecting men, at younger age than tobacco and alcohol related carcinomas and supposed to be mainly linked to changes in sexual behaviors over the past five decades \[[@pone.0170091.ref003]--[@pone.0170091.ref008]\]. Present in 45--90% of cases, high-risk HPVs are now considered the main etiologic agents of OPSCC in the United States and in Northern Europe \[[@pone.0170091.ref005], [@pone.0170091.ref009]\]. In Northeast Italy, the prevalence of HPV-driven OPSCC is conversely lower, at 20% \[[@pone.0170091.ref010]\].

Oral HPV infection is the presumed precursor of HPV-driven OPSCC. However, the natural history of oral HPV infection is not yet entirely understood. Estimating its prevalence in specific populations and identifying its determinants are, therefore, essential steps to devise appropriate prevention strategies. Studies investigating the prevalence of oral HPV infection in healthy subjects have, however, uncovered a high variability in the prevalence in different populations, with values ranging between 0.2% and 20.7% \[[@pone.0170091.ref011]--[@pone.0170091.ref033]\]. The two studies that have investigated its prevalence in healthy Italian populations produced quite different results \[[@pone.0170091.ref026],[@pone.0170091.ref027]\]: according to the first \[[@pone.0170091.ref026]\], which was carried out in 2007 on a series of healthy Sardinians, its prevalence was estimated at 18.4%, while the second, \[[@pone.0170091.ref027]\], which was carried out in 2012 on a series of healthy Italians living in a Northern region, produced a much lower figure (1.2%).

Part of a multicenter European project and coordinated by the German Cancer Research Center based in Heidelberg (Germany), this study aimed to investigate the prevalence of oral HPV infection in a large Italian population of healthy subjects. The study specifically set out to (i) determine oral HPV prevalence and genotype distribution in a sample of young adults, (ii) validate an oral rinse and gargle collection and storage protocol, and (iii) identify factors associated with oral HPV infection.

Materials and Methods {#sec002}
=====================

Study design and subjects {#sec003}
-------------------------

This cross-sectional study was conducted between July 2014 and January 2015. Five-hundred students, nurses and technicians studying and working at/for the University of Padua, were recruited. Inclusion criteria were age 18--35 years and signed informed consent. Exclusion criteria included history of head and neck cancer and ongoing diseases of the upper aerodigestive tract. Potential participants who were contacted during classes or through student representatives by email messages or telephone calls were informed that investigators would not register any identifying details and that anonymity would be protected. Subjects who agreed to participate signed informed consent forms. Each participant was given a questionnaire together with an oral rinse sample kit. Both were labeled with the same unique identification number. The study was approved by the local Clinical Trials Ethics Committee (Ethic vote 54/CE/AULSS9).

Questionnaire {#sec004}
-------------

Each participant was asked to answer an anonymous questionnaire (please see Appendix A in [S1 File](#pone.0170091.s001){ref-type="supplementary-material"}) investigating variables concerning age, sex, education level, HPV vaccination status (the number, dates and types of vaccinations), history of recurrent tonsillitis, previous tonsillectomy, use of tobacco, alcohol and/or illegal drugs, number of same- and opposite-sex partners for genital and oral sex, history of former and current infections (cutaneous and genital HPV, Herpes simplex virus types 1 and 2, Candida albicans, Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum, Trichomonas vaginalis, Gardnerella vaginalis, human immunodeficiency virus). Female participants were asked about the results of their Pap smears and if they had been treated for cervical lesions.

Oral rinse samples {#sec005}
------------------

Each participant received an oral rinse sampling kit and instructions for use. They were directed to rinse and gargle with 10 ml mouth wash solution (Listerine Cool Mint---Johnson & Johnson®) for 30 seconds. After alternating rinsing and gargling they were asked to expectorate into a sterile container that was sealed and consigned to one of the study coordinators. The specimens were stored at -20°C in the Pathology Department of the Treviso Regional Hospital and later sent to the German Cancer Research Center (DKFZ) in Heidelberg, Germany for HPV analyses.

DNA extraction {#sec006}
--------------

Oral rinse samples were thawed at room temperature, vortexed and 500 μL were used for automated DNA extraction. Extraction was done using the MagNa Pure 96 DNA and Viral NA Large Volume Kit on the platform of the MagNa Pure 96 instrument in combination with the 'Pathogen universal 500' protocol. DNA was eluted in 50 μL elution buffer (Roche, Mannheim, Germany) and stored at -20°C until further processing.

BSGP5+/6+-PCR/Multiplex HPV genotyping {#sec007}
--------------------------------------

The BSGP5+/6+-PCR/MPG assay comprises the BSGP5+/6+-PCR, which homogenously amplifies a \~150 bp amplicon from the L1 region of 51 mucosal HPV types, sequences of the β-globin gene and internal controls \[[@pone.0170091.ref034]\] and the subsequent MPG hybridization assay with bead-based Luminex xMAP suspension array technology that is able to simultaneously identify and quantify the 51 HPV types (12 high-risk HPV types: HPV16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59; one probably high-risk HPV type: HPV68; 7 possibly high-risk HPV types: HPV26, -53, -66, -67, -70, -73, and -82; HPV31 low-risk HPV types: HPV6, -7, -11, -13, -30, -32, -34, -40, -42, -43, -44, -54, -61, -62, -69, -71, -72, -74, -81, -83, -84, -85, -86, -87, -89, -90, -91, -97, -102, -106, and -114) and the β-globin gene \[[@pone.0170091.ref035]\]. Briefly, 5 μL DNA were used for PCR and amplification was performed utilizing the Multiplex PCR Kit (Qiagen, Hilden, Germany) using 0.2--0.5 μM of each BSGP5+ and 5´-biotinylated BSGP6+ primers and 0.15 μM of each β-globin primer MS3 and 5´-biotinylated MS10. Following PCR amplification, 10 μL of each reaction mixture was hybridized to bead-coupled probes, as described elsewhere \[[@pone.0170091.ref034]\]. Bound biotinylated amplimers were quantified using the Luminex 100 analyzer. The median reporter fluorescence intensity (MFI) of at least 100 beads was computed for each bead set in the sample.

Cut-off definition {#sec008}
------------------

The cut-off for each sample was defined as 5 + 1.5\*median net MFI of all 63 probes (specific for the 51 HPV types plus ß-globin, and internal controls for extraction, hybridization, and PCR performance). This sample-specific cut-off was subtracted from each net MFI value. Negative values were set to 0.

Presence of HPV {#sec009}
---------------

HPV-type was defined as "positive" if the type-specific MFI value was above the cut-off (\> 0 MFI). A sample was defined as "DNA valid" if either an HPV-type or ß-globin was above cut-off.

Sample size calculation {#sec010}
-----------------------

The size of the population that was required by our study was calculated using the following formula: $$n_{0} = \frac{u_{\alpha}{}^{2}\pi\left( 1 - \pi \right)}{\partial^{2}}$$ where *n*~0~ is the estimated sample size, *π* is the expected prevalence of the HPV infection, ∂ is the precision of the estimate, *α* is = 0.05, and *u*~*α*~ = 1.96. Based on data from a series of previous studies \[[@pone.0170091.ref036]\], we expected an all-type HPV prevalence of 5%. We calculated that a sample size of 457 subjects was needed in order to obtain a precision of the estimate of all-type HPV prevalence not exceeding ±2.5%. As we expected a participation rate of 75%, 600 subjects were invited to participate.

Statistical analysis {#sec011}
--------------------

Descriptive statistics were used to summarize the participants' characteristics (median, range, and proportion). HPV positive individuals were compared with HPV negatives to identify characteristics associated with oral HPV infection. The percentage of HPV positive of each group and the prevalence ratio (i.e. the prevalence of infection in exposed divided by the prevalence of infection in the non-exposed) with relative 95% confidence intervals (95% CI) were calculated. The chi-square test (or Fischer's exact test when the expected number in any cell was \<5) was used for comparisons between two categorical variables. For all the relevant comparisons p-values, calculated according to a two tailed probability distribution, are reported. The SPSS 17.0 Statistics (SPSS Inc, Chicago, IL) and STATA 13 software packages were used to compute 95% CI (StataCorp LP, College Station, TX).

Results {#sec012}
=======

Characteristics of the study population {#sec013}
---------------------------------------

We have no demographic information about the 38 subjects who declined to participate in the study. The recruitment process was concluded when we had recruited 500 participants who provided informed consent. The participants were all students, nurses, and technicians (253 females and 247 males) studying and working at/for the University of Padua ([Table 1](#pone.0170091.t001){ref-type="table"}). The median age of the participants was 23 years (range 19--35). The median age of females was 22 (range 19--35 years) and of males was 23 years (range 19--35 years). All participants were Caucasian.

10.1371/journal.pone.0170091.t001

###### Participants' characteristics by oral HPV status.

![](pone.0170091.t001){#pone.0170091.t001g}

  Characteristics                                    Total      HPV positive   Prevalence ratio   95% CI
  ---------------------------------- --------------- ---------- -------------- ------------------ --------
  Gender                             Female          253        10(4.0%)       1                  
  Male                               247             10(4.0%)   1.02           0.43--2.42         
  Age (years)                        19--24          333        15(4.5%)       1                  
  25--29                             98              2(2.0%)    0.45           0.11--1.95         
  30--35                             62              2(3.2%)    0.72           0.17--3.05         
  Missing data                       7               1          \-                                
  Education                          High school     365        16(4.4%)       1                  
  Degree                             134             4(3.0%)    0.68           0.23--2.00         
  Missing data                       1               0          \-                                
  Smoking                            Never/former    408        18(4.4%)       1                  
  Current                            88              2(2.3%)    0.52           0.12--2.18         
  Missing data                       4               0          \-                                
  Alcohol                            \<1drink/week   257        10(3.9%)       1                  
  \>1drink/week                      237             9(3.8%)    0.98           0.40--2.36         
  Missing data                       6               1          \-                                
  Illegal drug use                   Never           342        13(3.8%)       1                  
  Ever                               148             7(4.7%)    1.24           0.51--3.06         
  Missing data                       10              0          \-                                
  *Cannabis*                         148             7(4.7%)    \-                                
  *Cocaine*                          11              0(0.0%)    \-                                
  *Hallucinogenic*                   5               0(0.0%)    \-                                
  *Opiates*                          2               0(0.0%)    \-                                
  History of tonsillectomy           No              457        18(3.9%)       1                  
  Yes                                37              2(5.4%)    1.37           0.33--5.69         
  Missing data                       6               0          \-                                
  History of recurrent tonsillitis   No              461        19(4.1%)       1                  
  Yes                                33              1(3.0%)    0.74           0.10--5.32         
  Missing data                       6               0                                            
  HPV vaccination status             Unvaccinated    457        18(3.9%)       1                  
  Vaccinated                         43              2(4.7%)    1.18           0.28--4.92         

CI confidence interval; HPV human papillomavirus.

None of the males had been vaccinated against HPV, while 43/253 females (17.0%) had undergone HPV vaccination. Sixteen declared that they had received 3 doses of a quadrivalent HPV vaccine (Gardasil®), and four declared they had received 3 doses of a bivalent HPV vaccine (Cervarix®); the remaining 23 did not specify the vaccine type or the number of doses they had received ([Table 1](#pone.0170091.t001){ref-type="table"}).

More male participants (60.4% compared to 34.9% of females) reported having more than one drink a week and taking illegal drugs (40.8% compared to 20.4%. of the females, Table A in [S1 File](#pone.0170091.s001){ref-type="supplementary-material"}).

Males declared that they had more sex partners than women, i.e. 11.1% females and 25.7% males had \>5 lifetime sex partners and 13.2% females and 23.8% males had two or more sex partners during the last 12 months (Table B in [S1 File](#pone.0170091.s001){ref-type="supplementary-material"}).

Complications during sample collection {#sec014}
--------------------------------------

No complications were reported during the sampling process. All of the participants carried out the oral rinse protocol without any difficulty.

Oral HPV prevalence and HPV types {#sec015}
---------------------------------

All oral rinse and gargle samples were positive for β-globin. Twenty of 500 participants tested positive for oral HPV infection (prevalence 4.0%, 95% CI, 2.46%-6.11%). Out of the 51 HPV types that were tested, nine were detected in the study population (HPV6, -11, -16, -30, -52, -53, -56, -81, -90). The high-risk and low-risk HPV infection prevalence were 2.2% (95% CI, 1.10%-3.90%) and 2.0% (95% CI, 0.96%-3.65%), respectively. Nineteen of the HPV positive samples had single HPV-type; one had a co-infection (HPV16 and HPV81). HPV16 was the most prevalent HPV-type identified in 8/20 (40%) oral HPV-DNA positive participants (prevalence 1.6%; 95% CI, 0.63%-3.13%) ([Fig 1](#pone.0170091.g001){ref-type="fig"}).

![Number of HPV positive samples.\
Number of HPV genotypes detected in oral rinse and gargle samples of the 500 participants. One participant had a co-infection, HPV16 and HPV81. Black bars, high-risk HPV; grey bars, low-risk HPV. HPV human papillomavirus.](pone.0170091.g001){#pone.0170091.g001}

Characteristics and behaviors associated with oral HPV infection {#sec016}
----------------------------------------------------------------

The median age of oral HPV positive participants was 21 (range 19--33 years), and of HPV negative 23 years (range 19--35 years) (p = 0.100). The prevalence of oral HPV infection was 4.5% (95% CI, 2.54%-7.32%) in the 19--24 year-old group, 2.0% (95% CI, 0.25%-7.18%) in the 25--29 year-old group, and 3.2% (95% CI, 0.39%- 11.17%) in the 30--34 year-old group.

None of the variables investigated (gender, age, education, illegal drug use, tobacco smoking, alcohol consumption, history of tonsillectomy and of recurrent tonsillitis, number of sex and oral sex heterosexual and homosexual partners lifetime and over the previous 12 months) were statistically significantly associated with oral HPV infection (Tables [1](#pone.0170091.t001){ref-type="table"}, [2](#pone.0170091.t002){ref-type="table"}, and Table C in [S1 File](#pone.0170091.s001){ref-type="supplementary-material"}). A history of previous sexually transmitted infections was not significantly associated with oral HPV infection (Table D in [S1 File](#pone.0170091.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0170091.t002

###### Number of heterosexual sex partners stratified by oral HPV status.

![](pone.0170091.t002){#pone.0170091.t002g}

  Characteristics                                   Total      HPV positive   Prevalence ratio   95% CI
  ------------------------------------------- ----- ---------- -------------- ------------------ ------------
  Heterosexual partners/lifetime              0     57         4 7.0%)        1.99               0.56--7.16
  1                                           142   5(3.5%)    1                                 
  2--5                                        188   7(3.7%)    1.06           0.34--3.26         
  6--10                                       59    4(6.8%)    1.32           0.36--4.79         
  11--19                                      18    0(0.0%)                                      
  \>19                                        9     0(0.0%)                                      
  Missing data                                27    0          \-                                
  Heterosexual partners/last 12 months        0     99         6(6.1%)        1.97               0.72--5.40
  1                                           293   9(3.1%)    1                                 
  2--5                                        81    5(6.2%)    1.85           0.64--5.38         
  6--10                                       4     0(0.0%)                                      
  11--19                                      2     0(0.0%)                                      
  \>19                                        1     0(0.0%)                                      
  Missing data                                20    0          \-                                
  Oral heterosexual partners/lifetime         0     80         4(5.0%)        0.88               0.27--2.83
  1                                           141   8(5.7%)    1                                 
  2--5                                        183   5(2.7%)    0.48           0.16--1.44         
  6--10                                       46    3(6.5%)    0.74           0.20--1.72         
  11--19                                      14    0(0.0%)                                      
  \>19                                        11    0(0.0%)                                      
  Missing data                                25    0          \-                                
  Oral heterosexual partners/last 12 months   0     118        7(5.9%)        1.62               0.63--4.15
  1                                           273   10(3.7%)   1                                 
  2--5                                        76    3(3.9%)    0.96           0.27--3.42         
  6--10                                       4     0(0.0%)                                      
  11--19                                      4     0(0.0%)                                      
  \>19                                        1     (0.0%)                                       
  Missing data                                24    0          \-                                

CI confidence interval; HPV human papillomavirus.

Among the 90 women who declared to have undergone Pap smear testing, two were oral HPV positive, eleven had abnormal Pap smear results and 6 of them underwent treatment. One of oral HPV positive women had an abnormal Pap smear results ([Table 3](#pone.0170091.t003){ref-type="table"}).

10.1371/journal.pone.0170091.t003

###### History of Pap smear testing and oral HPV status.

![](pone.0170091.t003){#pone.0170091.t003g}

  Pap test            Total female   HPV positive   Prevalence ratio                              95% CI
  ------------------- -------------- -------------- --------------------------------------------- --------------
  Never               140            7 (5.0%)                                                     
  Underwent testing   90             2 (2.2%)       0.44                                          0.09--2.09
  Missing data        23             1              \-                                            
  *Abnormalities*     11             1 (9.1%)       6.64[^a^](#t003fn002){ref-type="table-fn"}    0.45--98.58
  *Treatment*         6              1 (16.7%)      12.00[^a^](#t003fn002){ref-type="table-fn"}   0.65--178.79

CI confidence interval; HPV human papillomavirus.

^a^ Prevalence ratio versus women with normal Pap smear results.

Two of the vaccinated women were oral HPV positive, i.e. one was HPV16 positive and the other was HPV6 positive ([Table 1](#pone.0170091.t001){ref-type="table"}). The HPV16 positive woman had received three doses of Gardasil® in 2012 and the HPV6 positive woman did not specify the type or number of doses of vaccine she had received.

Discussion {#sec017}
==========

This is the first study investigating the prevalence of oral HPV infection in a large Italian population of young adults. In the light of the dramatic rise in HPV-associated OPSCC, the study set out to (i) determine oral HPV prevalence and genotype distribution, (ii) validate a reproducible oral rinse sampling and storage protocol, and (iii) identify factors associated with oral HPV infection, in a series of young adults from Italy.

As oral cytobrush or swab samples were found to provide insufficient DNA quality compared to oral rinse and gargle \[[@pone.0170091.ref037]--[@pone.0170091.ref039]\], we adopted this second methodology for the present study. Our oral rinse sampling protocol can be considered safe and well-tolerated as no complications/problems were reported, and, in fact, all of the participants completed the rinsing/gargling sequence in 30 seconds. All samples were positive for the ß-globin gene confirming that the processing and storage procedures were indeed efficacious. This sampling procedure may also be applied to monitor patients treated for HPV-driven OPSCC for the early detection of local relapses \[[@pone.0170091.ref040]\] and to identify a high-risk HPV infection in patients with an occult SCC metastatic to neck lymph nodes, thus guiding the search of the hidden primary in the oropharynx \[[@pone.0170091.ref041]\].

A bead-based multiplex genotyping of 51 mucosal HPV-types, a powerful tool for genotyping single and multiple HPV infections that is suitable for large-scale epidemiological studies, was used here \[[@pone.0170091.ref035]\]. The overall oral HPV infection prevalence found in our population sample was 4.0% with HPV16 being the most frequent genotype found (1.2%). The prevalence of oral HPV infection was recently calculated in a systematic review of the literature including around 4,600 healthy individuals from different countries and continents \[[@pone.0170091.ref036]\]. Interestingly, the overall prevalence was comparable to our study: 4.5% and 1.3% for all types of HPV infection and HPV16 infection, respectively. The only two studies \[[@pone.0170091.ref026],[@pone.0170091.ref027]\] that have investigated the prevalence of oral HPV infection in samples of healthy Italian population from quite different cohorts produced ambiguous data and high prevalence variability (1.2% and 18.4%, respectively). A high inconsistency in the overall prevalence of oral HPV infection is in common with other studies, with values ranging between 0.2% and 20.7% \[[@pone.0170091.ref011]--[@pone.0170091.ref033]\]. This may partially be related to the different inclusion criteria, clinical setting, sampling methods and detection assays. However, it could also reflect real differences in HPV exposure in different geographical and social contexts as well as biological and genetic differences in the population investigated. Supporting this hypothesis, two large studies both conducted in \>5,000 individuals from United States \[[@pone.0170091.ref017]\] and China \[[@pone.0170091.ref019]\], reported an overall prevalence of oral HPV infection of 6.8% and 0.6%, respectively. Of interest, these data reflect the rates of HPV-positive OPSCC in these different areas \[[@pone.0170091.ref042],[@pone.0170091.ref043]\]. The percentage of HPV-driven OPSCC has been reported to be low in Northeast Italy \[[@pone.0170091.ref010]\]. A similar prevalence of oral HPV16 infection in the young population of our study and in the US population studied \[[@pone.0170091.ref017]\] may reflect changing sexual habits in the Italian population, and it is possible that we will see an increase in HPV-driven OPSCC in the years to come.

We did not find statistically significant associations between oral HPV infection and age, gender, tobacco smoking, abuse of alcohol or illegal drugs, number of sex and oral sex partners, history of infections and of abnormal pap smears, previous tonsillectomy or recurrent tonsillitis and vaccination against HPV. It cannot, however, be excluded that even if the population studied was rather large, the overall prevalence of oral HPV infection was too low to allow us to investigate the determinants of the infection. The finding of a higher risk of HPV infection in subjects without any partners in their lifetime was quite unexpected, but could be compatible with a purely random data fluctuation. Furthermore, given our sample size, we had 50% power to detect a significant difference in prevalence, just as that observed by Chaturvedi et al. between the exposed and unexposed subjects \[[@pone.0170091.ref004]\]. In an US population (aged 14--69 years) the prevalence of oral HPV infection was 6.9% with peak prevalence of 7.3% among participants aged 30--34 years and 11.4% among participants aged 60--64 years \[[@pone.0170091.ref017]\]. An increasing prevalence with age was also found in an Australian study \[[@pone.0170091.ref011]\] (aged 18--35 years) which reported that the overall prevalence of 2.3% had a peak of 4.8% in the 25--35 age group. The incongruous pattern that was noted (but without statistically significant differences) in our population in which the prevalence was higher in the 19--24 year-old group (4.8%) than in the 25--29 (2.0%) and 30--35 year-old groups (3.2%) could be explained by different behavior trends in younger population groups living in the same geographic areas.

Several studies \[[@pone.0170091.ref011],[@pone.0170091.ref044]\] have found a higher prevalence in men; this finding could be partly related to the significantly higher number of lifetime sex partners in men than in women \[[@pone.0170091.ref017],[@pone.0170091.ref044]\]. It is important to remember, however, that men traditionally tend to over-report and women to under-report sexual partnerships \[[@pone.0170091.ref044]\]. Although the men participating in our study did indeed report a higher number of lifetime sex partners (p\<0.001), of sex partners during last 12 months (p = 0.011), and of lifetime oral sex partners (p\<0.001), just as in other studies \[[@pone.0170091.ref019],[@pone.0170091.ref045]\], no gender difference was observed in the prevalence of oral HPV infection in our study population.

A recent Danish study \[[@pone.0170091.ref046]\] reported that tonsillectomy significantly reduced the risk of tonsillar carcinoma diagnosis \[incidence rate ratio (RR), 0.40; 95% CI, 0.22--0.70\]. In view of the tropism of HPV to tonsillar tissue \[[@pone.0170091.ref047]\], it would be interesting to study the prevalence of oral HPV infection in a large population of individuals who had undergone tonsillectomy. Although we did not find that tonsillectomy had a significantly protective effect on oral HPV infection, it was indeed detected in two individuals who underwent the operation. It is not in any case possible to establish the site of infection using the methodology outlined here. The base of the tongue, rich in lymphoepithelial tissue which is the preferential substratum for HPV infection, could be the site of infection in those individuals with previous tonsillectomy. Some 17% of the female participants enrolled in our study had been vaccinated against HPV. The only studies \[[@pone.0170091.ref039],[@pone.0170091.ref048],[@pone.0170091.ref049]\] investigating the effect of HPV vaccination on oral HPV infection in females reported a lower prevalence of oral HPV infection in the vaccinated group. Here in this region of Italy, the most utilized HPV vaccine is the quadrivalent vaccine (Gardasil®) that provides protection against HPV types 6, 11, 16 and 18. Unexpectedly, two vaccinated individuals participating in our study resulted positive to oral HPV infection: one was HPV16 positive and the other was HPV6 positive. There were no statistically significant differences in oral HPV infection prevalence in the vaccinated and unvaccinated groups. It is in any case possible that the oral HPV infection had already been acquired before they were vaccinated, or that it was a very recent infection, as the immune system needs some months to be activated and clear the infection.

Since there is not yet any validated method to screen for HPV-driven OPSCC \[[@pone.0170091.ref049]\], HPV vaccination seems the best path to prevent oral HPV infection and to halt the rise in HPV-driven OPSCC incidence. Just as in other European countries, recent studies and findings have led to new cost-effectiveness calculations that favor expanding the HPV vaccination program to boys \[[@pone.0170091.ref050]\] in view of new updated models \[[@pone.0170091.ref051]\]. The Veneto and other Italian regions \[[@pone.0170091.ref052]\] have, indeed, switched to and are implementing universal vaccination programs.

Conclusions {#sec018}
===========

This is the first large study conducted on the prevalence of oral HPV infection in Italy. The reproducible oral rinse sampling/storage protocol outlined here was efficient and well tolerated. The overall prevalence of oral HPV infection in a population of young Italians was 4.0% with HPV16 being by far the most frequently detected genotype. Risk factors for oral HPV infection are nevertheless still unclear and further studies are certainly warranted. The data presented here can moreover be used to guide further research and for systematic reviews and meta-analysis.

Supporting Information {#sec019}
======================

###### 

**Table A Characteristics of study participants stratified by gender.** HPV human papillomavirus**. Table B Number of heterosexual sex partners stratified by gender. Table C Number of homosexual sex partners stratified by oral HPV status.** HPV human papillomavirus**. Table D History of previous infections stratified by oral HPV status.** HPV human papillomavirus; HIV Human immunodeficiency virus**. Appendix A Self-administered survey.**

(DOCX)

###### 

Click here for additional data file.

This study was partially supported by the European Commission, grant HPV_AHEAD (FP7-HEALTH-2011-282562). We thank laboratory technicians Birgit Aengeneyndt and André Leischwitz of the German Cancer Research Center for excellent technical assistance. The authors also express acknowledgment to all students, nurses and technicians involved in the study for their cooperation.

[^1]: **Competing Interests:**MP is inventor of patents owned by DKFZ in the field of HPV DNA diagnostic assays: Novel Broad Spectrum BS\-\--GP5+/6+PCR for Homogeneous Amplification of Human Alpha Papillomaviruses. Patent EP 2195468, US 8,202,694. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

[^2]: **Conceptualization:** VL D. Holzinger MP PBR.**Data curation:** VL D. Holzinger D. Höfler AM.**Formal analysis:** PGR.**Funding acquisition:** MP PBR.**Investigation:** VL D. Holzinger D. Höfler AM.**Methodology:** VL D. Holzinger D. Höfler MP PBR.**Project administration:** D. Holzinger MP.**Resources:** D. Holzinger MP PBR.**Supervision:** ADM MCDM MP PBR.**Validation:** MP D. Holzinger PBR.**Writing -- original draft:** VL D. Holzinger MP PBR.**Writing -- review & editing:** D. Holzinger D. Höfler ADM MCDM MP PBR.

[^3]: ‡ These authors also contributed equally to this work.
